Phaseline

Targets › PPAT

PPAT (Amidophosphoribosyltransferase): drug programs, companies and trials

8 programs from 8 companies in 9 trials: 3 Phase 3, 2 Phase 4, 2 Phase 2, 2 Phase 1; Immunology, Oncology, Cardiovascular; next expected readout Dec 2026.

Catalyzes the formation of phosphoribosylamine from phosphoribosylpyrophosphate (PRPP) and glutamine. (UniProt, Q06203)

Open in Phaseline: the race on PPAT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Children's Hospital of Fudan UniversityAzathioprine
Amidophosphoribosyltransferase inhibitor
PPATPhase 4Crohn DiseaseDec 2026
Medical University of WarsawAzathioprine
Amidophosphoribosyltransferase inhibitor
PPATPhase 4MyocarditisSep 2027
Hospices Civils de LyonAzathioprine
Amidophosphoribosyltransferase inhibitor
PPATPhase 3Central Nervous System InflammationDec 2026
Assistance Publique - Hôpitaux de ParisAzathioprine
Amidophosphoribosyltransferase inhibitor
PPATPhase 3Acute Demyelinating SyndromeApr 2027
University of NebraskaAzathioprine
Amidophosphoribosyltransferase inhibitor
PPATPhase 3Rheumatoid ArthritisMar 2028
University of PennsylvaniaAzathioprine
Amidophosphoribosyltransferase inhibitor
PPATPhase 2Relapsing Polychondritis; Primary Cutaneous VasculitisJul 2027
University Hospital, AntwerpMercaptopurine
Amidophosphoribosyltransferase inhibitor
PPATPhase 1Acute Myeloid Leukemia, in RelapseDec 2026
Haukeland University HospitalMercaptopurine
Amidophosphoribosyltransferase inhibitor
PPATPhase 1Acute Myeloid Leukemia, AdultSep 2029

Conditions

Rheumatoid Arthritis (1) Central Nervous System Inflammation (1) Crohn Disease (1) Myocarditis (1) Relapsing Polychondritis (1) Primary Cutaneous Vasculitis (1) Acute Myeloid Leukemia, in Relapse (1) Acute Demyelinating Syndrome (1) Acute Myeloid Leukemia, Adult (1)

Modalities

small molecule (5), mixed (2), antibody (1)

Companies

University of Nebraska (1) Hospices Civils de Lyon (1) Children's Hospital of Fudan University (1) Medical University of Warsaw (1) University of Pennsylvania (1) University Hospital, Antwerp (1) Assistance Publique - Hôpitaux de Paris (1) Haukeland University Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.